Tempest Therapeutics, Inc. — Form 8-K
Filed July 22, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Tempest Therapeutics signed a Product Development and IIT Collaboration Agreement with Hebei Senlang Biotechnology (effective July 17, 2026) to conduct investigator-initiated trials of TPST-4003, a CD7-targeted in vivo CAR-T candidate, in China. Senlang will execute the trial in approximately 10 patients with myasthenia gravis or multiple sclerosis, with first patient dosing expected Q4 2026. Tempest will pay Senlang $1.5–$2.0 million per product for development, manufacturing, IIT support, and data delivery. Senlang receives an exclusive 90-day option post-trial to negotiate a definitive license agreement for China commercialization rights; Tempest retains all ex-China and global rights.
Why this rating
Development cost is 5–7% of company market cap; moderate for early-stage biotech. Advances lead program clinically but not transformational alone; keeps capital in house via contractor model.
See more from July 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.